HK1208341A1 - Substituted pyrazolone compounds and methods of use - Google Patents
Substituted pyrazolone compounds and methods of useInfo
- Publication number
- HK1208341A1 HK1208341A1 HK15107639.5A HK15107639A HK1208341A1 HK 1208341 A1 HK1208341 A1 HK 1208341A1 HK 15107639 A HK15107639 A HK 15107639A HK 1208341 A1 HK1208341 A1 HK 1208341A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- pyrazolone compounds
- substituted pyrazolone
- substituted
- compounds
- Prior art date
Links
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676944P | 2012-07-28 | 2012-07-28 | |
US201261679416P | 2012-08-03 | 2012-08-03 | |
PCT/US2013/051174 WO2014022116A2 (en) | 2012-07-28 | 2013-07-19 | Substituted pyrazolone compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208341A1 true HK1208341A1 (en) | 2016-03-04 |
Family
ID=50028432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107639.5A HK1208341A1 (en) | 2012-07-28 | 2015-08-07 | Substituted pyrazolone compounds and methods of use |
Country Status (11)
Country | Link |
---|---|
US (1) | US8969388B1 (ru) |
EP (2) | EP2879676B1 (ru) |
JP (2) | JP6342393B2 (ru) |
AU (1) | AU2013296897B2 (ru) |
BR (1) | BR112015001528B1 (ru) |
CA (1) | CA2876246C (ru) |
ES (1) | ES2634414T3 (ru) |
HK (1) | HK1208341A1 (ru) |
MX (1) | MX2015001424A (ru) |
RU (1) | RU2650895C2 (ru) |
WO (2) | WO2014022117A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2650895C2 (ru) * | 2012-07-28 | 2018-04-18 | Саншайн Лейк Фарма Ко., Лтд. | Соединения замещенных пиразолонов и способы использования |
JP6500037B2 (ja) * | 2014-04-22 | 2019-04-10 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc | 二環式ピラゾロン化合物および使用方法 |
WO2016061231A1 (en) * | 2014-10-14 | 2016-04-21 | Deciphera Pharmaceuticals, Llc | Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression |
CN106467541B (zh) | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CN105153026B (zh) * | 2015-08-21 | 2018-02-02 | 江西科技师范大学 | 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用 |
CN105237523B (zh) * | 2015-10-08 | 2018-06-01 | 深圳市博圣康生物科技有限公司 | 嘧啶衍生物及其制备方法、用途 |
CN111956646B (zh) | 2016-03-02 | 2023-07-25 | 麦迪维尔股份公司 | 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 |
AR108107A1 (es) * | 2016-04-29 | 2018-07-18 | Syngenta Participations Ag | Proceso para preparar compuestos herbicidas |
KR102507660B1 (ko) * | 2016-10-10 | 2023-03-07 | 바스프 에스이 | 니트로 화합물의 연속적 액체상 수소화에서의 알칼리 금속, 알칼리 토금속 또는 희토류 금속 이온에 의한 촉매 개질 |
MX2019008458A (es) | 2017-01-17 | 2019-12-02 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos. |
WO2019228252A1 (zh) | 2018-06-01 | 2019-12-05 | 杭州阿诺生物医药科技有限公司 | 一种高活性csf1r抑制剂化合物 |
CN109096250A (zh) * | 2018-09-25 | 2018-12-28 | 辽宁大学 | 含哒嗪酮的4-苯氧基吡啶类化合物及其应用 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
JP7293404B2 (ja) * | 2019-05-24 | 2023-06-19 | メッドシャイン ディスカバリー インコーポレイテッド | c-MET/AXL阻害剤の結晶形 |
EP4077690A4 (en) * | 2019-12-20 | 2024-04-10 | Engine Biosciences Pte Ltd | METHODS AND COMPOSITIONS FOR TREATING CANCER |
CN114213404A (zh) * | 2021-12-27 | 2022-03-22 | 武汉九州钰民医药科技有限公司 | Vegfr抑制剂替沃扎尼的合成工艺 |
CN114796227B (zh) * | 2022-05-30 | 2023-12-01 | 中山大学 | Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物 |
CN114903996B (zh) * | 2022-06-22 | 2023-10-20 | 武汉大学中南医院 | Hedgehog通路的特异性抑制剂在制备用于治疗宫腔粘连的药物中的应用 |
CN116283920B (zh) * | 2023-03-31 | 2024-04-16 | 贵州医科大学 | 2,4-二取代吡啶类化合物及其应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
WO1995015373A2 (en) | 1993-11-30 | 1995-06-08 | Mcgill University | Inhibition of dna methyltransferase |
US5578716A (en) | 1993-12-01 | 1996-11-26 | Mcgill University | DNA methyltransferase antisense oligonucleotides |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6268137B1 (en) | 1996-05-22 | 2001-07-31 | Methylgene, Inc. | Specific inhibitors of DNA methyl transferase |
US6020318A (en) | 1997-05-30 | 2000-02-01 | Methylgene, Inc. | DNA methyltransferase genomic sequences and antisense oligonucleotides |
WO1998054313A2 (en) | 1997-05-30 | 1998-12-03 | Mcgill University | Dna methyltransferase genomic sequences and antisense oligonucleotides |
US6066625A (en) | 1998-02-03 | 2000-05-23 | Methylgene, Inc. | Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
US6953783B1 (en) | 1998-10-19 | 2005-10-11 | Methylgene, Inc. | Modulation of gene expression by combination therapy |
KR20020007398A (ko) | 1999-05-03 | 2002-01-26 | 추후제출 | 히스톤 탈아세틸화효소의 억제 |
DK1233958T3 (da) | 1999-11-23 | 2011-10-17 | Methylgene Inc | Hæmmere af histondeacetylase |
ATE489360T1 (de) | 2000-03-24 | 2010-12-15 | Methylgene Inc | Inhibitoren der histon-deacetylase |
EP2093292A2 (en) | 2000-03-24 | 2009-08-26 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
EP1429765A2 (en) | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
JP2006503082A (ja) | 2002-10-17 | 2006-01-26 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
CA2539117A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2542653A1 (en) * | 2003-10-16 | 2005-04-28 | Chiron Corporation | Substituted benzazoles and use thereof as inhibitors of raf kinase |
AU2005225471B2 (en) | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
ES2438017T3 (es) | 2004-07-30 | 2014-01-15 | Methylgene Inc. | Inhibidores de la señalización del receptor del VEGF y del receptor del HGF |
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
US7851489B2 (en) | 2006-11-08 | 2010-12-14 | Bristol-Myers Squibb Company | Pyridinone compounds |
JP5314050B2 (ja) | 2008-01-23 | 2013-10-16 | ブリストル−マイヤーズ スクイブ カンパニー | 4−ピリジノン化合物および癌についてのその使用 |
JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 4−ピリジノン化合物および癌についてのその使用 |
WO2009108670A1 (en) | 2008-02-28 | 2009-09-03 | Merck Serono S.A. | Protein kinase inhibitors and use thereof |
EP2288383A1 (en) * | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
CA2738583A1 (en) * | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
KR100961410B1 (ko) | 2008-10-14 | 2010-06-09 | (주)네오팜 | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 |
EP2532657B9 (en) * | 2008-10-14 | 2017-04-19 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
JP5583751B2 (ja) | 2009-03-21 | 2014-09-03 | クイ ニング | アミノエステル誘導体、その塩、及び使用方法 |
AU2010281368C1 (en) | 2009-08-06 | 2016-08-04 | Merck Patent Gmbh | Novel bicyclic urea compounds |
CN102140093A (zh) | 2010-02-03 | 2011-08-03 | 上海源力生物技术有限公司 | 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用 |
AU2011248441A1 (en) | 2010-04-29 | 2012-12-20 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
KR101538707B1 (ko) | 2010-07-14 | 2015-07-22 | 베타 파머수티컬 컴퍼니 리미티드 | c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체 |
AU2011295441B2 (en) | 2010-08-27 | 2015-04-09 | Merck Patent Gmbh | Furopyridine derivatives |
CN103391773A (zh) * | 2010-09-27 | 2013-11-13 | 埃克塞里艾克西斯公司 | 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂 |
RU2568258C2 (ru) | 2011-02-28 | 2015-11-20 | Саншайн Лейк Фарма Ко., Лтд | Замещенные соединения хинолина и способы их использования |
CN102816175B (zh) | 2011-06-09 | 2015-12-16 | 上海汇伦生命科技有限公司 | 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途 |
EP2739143B1 (en) | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
BR112014012407A2 (pt) | 2011-11-22 | 2017-06-06 | Deciphera Pharmaceuticals Llc | amidas de piridona e análogos exibindo propriedades anti-câncer e anti-proliferativas |
WO2013180949A1 (en) | 2012-05-27 | 2013-12-05 | Ning Xi | Substituted quinoline compounds and methods of use |
RU2650895C2 (ru) * | 2012-07-28 | 2018-04-18 | Саншайн Лейк Фарма Ко., Лтд. | Соединения замещенных пиразолонов и способы использования |
-
2013
- 2013-07-19 RU RU2015106605A patent/RU2650895C2/ru not_active Application Discontinuation
- 2013-07-19 JP JP2015524334A patent/JP6342393B2/ja active Active
- 2013-07-19 MX MX2015001424A patent/MX2015001424A/es unknown
- 2013-07-19 WO PCT/US2013/051175 patent/WO2014022117A1/en active Application Filing
- 2013-07-19 ES ES13826459.3T patent/ES2634414T3/es active Active
- 2013-07-19 CA CA2876246A patent/CA2876246C/en active Active
- 2013-07-19 WO PCT/US2013/051174 patent/WO2014022116A2/en active Application Filing
- 2013-07-19 JP JP2015524333A patent/JP6342392B2/ja active Active
- 2013-07-19 US US13/945,925 patent/US8969388B1/en not_active Expired - Fee Related
- 2013-07-19 EP EP13825325.7A patent/EP2879676B1/en not_active Not-in-force
- 2013-07-19 AU AU2013296897A patent/AU2013296897B2/en active Active
- 2013-07-19 BR BR112015001528-0A patent/BR112015001528B1/pt not_active IP Right Cessation
- 2013-07-19 EP EP13826459.3A patent/EP2879677B1/en active Active
-
2015
- 2015-08-07 HK HK15107639.5A patent/HK1208341A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013296897A1 (en) | 2014-12-18 |
JP6342392B2 (ja) | 2018-06-13 |
RU2015106605A (ru) | 2016-09-20 |
EP2879677B1 (en) | 2017-06-14 |
BR112015001528A2 (pt) | 2017-08-22 |
WO2014022116A3 (en) | 2015-07-16 |
WO2014022116A2 (en) | 2014-02-06 |
BR112015001528B1 (pt) | 2020-12-22 |
US8969388B1 (en) | 2015-03-03 |
JP2015523390A (ja) | 2015-08-13 |
WO2014022117A1 (en) | 2014-02-06 |
JP2015530975A (ja) | 2015-10-29 |
EP2879676A4 (en) | 2015-12-09 |
ES2634414T3 (es) | 2017-09-27 |
AU2013296897B2 (en) | 2015-09-17 |
EP2879676A1 (en) | 2015-06-10 |
EP2879677A2 (en) | 2015-06-10 |
JP6342393B2 (ja) | 2018-06-13 |
CA2876246C (en) | 2019-05-07 |
RU2650895C2 (ru) | 2018-04-18 |
MX2015001424A (es) | 2016-03-09 |
WO2014022116A8 (en) | 2015-04-02 |
EP2879676B1 (en) | 2017-06-14 |
EP2879677A4 (en) | 2016-06-01 |
CA2876246A1 (en) | 2014-02-06 |
US20150050239A1 (en) | 2015-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181628T1 (hr) | Spojevi i postupci za njihovu upotrebu | |
HK1208341A1 (en) | Substituted pyrazolone compounds and methods of use | |
HK1208439A1 (en) | 5-azaindazole compounds and methods of use 5- | |
ZA201405248B (en) | Anesthetic compounds and related methods of use | |
EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
EP2938341A4 (en) | Heterocyclic compounds and methods for the use thereof | |
ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
IL244268A0 (en) | Heterocyclic compounds and methods of use | |
ZA201406082B (en) | Use of ccr3-inhibitors | |
PT3019477T (pt) | Compostos heterocíclicos e métodos para a sua utilização | |
EP3054974A4 (en) | Glycan-interacting compounds and methods of use | |
EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
AU2012900650A0 (en) | Compounds and methods of their use | |
AU2012900651A0 (en) | Compounds and methods of their use |